

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Holmes, et al.

23 April 1996

08/612,929

Group Art Unit No.:

Filed:

For:

March 7, 1996 Examiner: EXAMINENT IL4 ANTIBODIES USEFUL IN TREATMENT OF IL4

MEDIATED DISORDERS

Commissioner of Patents and Trademarks Washington, D.C. 20231

## FILING OF A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.§1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not. however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited reference is enclosed, except for those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted.

Attorney for Applicants Registration No. 34,028

SMITHKLINE BEECHAM CORPORATION Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939 Phone (610) 270-5024

Facsimile (610) 270-5090

n:\jas\pto\p50186-2\supplids.doc